# Newsroom Canonical URL: https://biopharmsignal.com/news/CNST/newsroom-39164465 Ticker: CNST Company: Constellation Pharmaceuticals Source: Constellation Pharmaceuticals Published: 2026-07-06 07:00 EST Original Source URL: https://www.morphosys.com/en/news/all ## Summary Review recent and past Novartis healthcare news stories, including media releases and featured information. ## Article Body About Board of Directors Giovanni Caforio Simon Moroney Nancy C. Andrews Ton Buechner Patrice Bula Elizabeth (Liz) Doherty Bridgette Heller Frans van Houten Elizabeth McNally Ana de Pro Gonzalo Charles Swanton John D. Young Charlotte Pamer-Wieser Executive Committee Vasant (Vas) Narasimhan Shreeram Aradhye Victor Bulto Aharon (Ronny) Gal Karen L. Hale Patrick Horber Rob Kowalski Steffen Lang Fiona Marshall Mukul Mehta Lutz Hegemann Teresa Jose Michelle Weese Products Therapeutic areas Cardiovascular, renal and metabolic Immunology Neuroscience Oncology People and culture Inclusion Promoting inclusion Building belonging Parental leave Caring for the mental health and wellbeing of our people Novartis Gene Therapies Manufacturing Quality Novartis quality management system (QMS) Audit program and regulatory inspections Product and patient safety training Product recalls Third-party suppliers Novartis and the European Union (EU) Awards and recognition About Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 296 million people worldwide. Patients and caregivers Healthcare professionals Medical congresses and events ASCO Annual Meeting ASCO 2023 Products Novartis pipeline Managed Access Programs Zolgensma® Global Managed Access Program (gMAP) Managed Access patient privacy notice and consent templates Novartis external funding Healthcare professional resources by country Investigator-initiated trials / studies Novartis medical information Submit medical enquiry Payments to Healthcare Professionals Healthcare professionals Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information. Research and development Technology platforms Research disease areas Cardiovascular and metabolic disease research at Novartis Diseases of Aging and Regenerative medicine (DARe) DAx: exploratory disease research at Novartis Global Health disease area research at Novartis Immunology disease research at Novartis Neuroscience research at Novartis Oncology research at Novartis Novartis pipeline Research collaborations Collaborations Research & development Discover how Novartis turns breakthrough science into transformative, high-value treatments. ESG Access Creating sustainable business models Value-based pricing Sub-Saharan Africa Donations Novartis access principles Novartis oncology access Patents and licensing Environmental sustainability Nature Climate Ethics, risk and compliance Ethical behavior Compliance Human rights Learning and engagement Integrated risk assurance Global health Pandemic preparedness Chagas disease Leprosy Malaria Sickle cell disease (SCD) Novartis Foundation Inclusion ESG index Reporting and transparency hub ESG rating performance Patient organization funding Payments to healthcare professionals Public policy Animal research Environmental, social and governance Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Investors Event calendar Financial data Novartis annual results Novartis quarterly results Novartis SEC filings Product sales Fixed-income securities Expected currency impact Share data and analysis Share monitor Dividend information Share ownership Share overview Return on investment calculator Shareholder information General Meetings American Depositary Receipts (ADR) Share buyback Frequently asked questions Company overview Corporate governance Reporting and transparency hub ESG rating performance Reporting archive Social Impact & Sustainability targets Publications order form ESG Investors Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting. News Careers Career search Our business functions Careers in research and development Careers in operations Careers in commercial and sales Careers in global functions Why Novartis Career hub Temporary contracts Early careers Graduates Students US Biomedical Research internship programs Community exploration and learning lab (CELL) Careers Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today. Clinical trials Partnering Supplier portal Report side effects Contacts Home Working together, we can reimagine medicine to improve and extend people’s lives. ## Recent Company News - 2026-07-06 07:00 EST — [Newsroom](https://biopharmsignal.com/news/CNST/newsroom-39164465) — Source: Constellation Pharmaceuticals - 2026-05-26 07:52 EST — [Stories](https://biopharmsignal.com/news/CNST/stories-aabf236c) — Source: Constellation Pharmaceuticals - 2026-03-30 09:12 EST — [Stories](https://biopharmsignal.com/news/CNST/stories-dc0f92b0) — Source: Constellation Pharmaceuticals ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) - 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)